SCHEMBL22632307

SCHEMBL22632307

CC(=O)NCCc1cc(=O)oc2cc(N3CCN(C)CC3)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 2/20 0.53
▸ MTNR1B P49286 2/20 0.53
▸ ASAH1 Q13510 1/20 0.45
▸ NPC1 O15118 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MTHFD2 P13995 1/20 0.42
▸ HSD17B3 P37058 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.40
▸ GAA P10253 3/20 0.40
▸ ERAP1 Q9NZ08 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ DRD2 P14416 1/20 0.40
▸ DRD4 P21917 1/20 0.40
▸ SLC18A1 P54219 1/20 0.40
▸ SLC18A2 Q05940 1/20 0.40
▸ MMP12 P39900 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24623270 0.89 DRD4 (0.45) MTNR1AMTNR1BASAH1NPC1LMNA
SCHEMBL22632086 0.86 SLC18A1 (0.45) ASAH1NPC1LMNATP53MAPK1
SCHEMBL24623581 0.86 DRD2 (0.48) MTNR1AMTNR1BASAH1NPC1LMNA
SCHEMBL24623268 0.83 MAPT (0.42) ASAH1NPC1LMNATP53MAPK1
SCHEMBL22632226 0.78 MTNR1B (0.60) MTNR1AMTNR1BHSD17B3ALDH1A1GAA
SCHEMBL22632322 0.76 MTNR1A (0.82) MTNR1AMTNR1BALDH1A1GAAKDM4E
SCHEMBL22632228 0.76 MTNR1A (0.58) MTNR1AMTNR1BNPC1LMNAHSD17B3
SCHEMBL22632306 0.72 MTNR1B (0.53) MTNR1AMTNR1BHSD17B3ALDH1A1GAA
SCHEMBL15992772 0.71 CHRNA7 (0.49) MAPK1MTHFD2MAPTALDH1A1GAA
SCHEMBL22632089 0.71 ALDH1A1 (0.67) MTNR1AMTNR1BNPC1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020223174-A1 COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER HEALTH RESEARCH, INC. (US) 2020-11-05 — — WO disclosed
Send feedback